Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00867087 · ClinicalTrials.gov registry record · Phase 2

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

A Phase 2 study of Lymphoma, B-Cell, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
64
Enrollment target
20
Study locations

NCT00867087 is a Phase 2 study of Lymphoma, B-Cell that has completed, run by Pfizer. The registered enrollment target is 64 participants, below the 199-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00867087, a Phase 2 study of Lymphoma, B-Cell, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
64 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.

Conditions Studied

Lymphoma, B-Cell

Interventions

  • DRUG rituximab
  • DRUG inotuzumab ozogamicin (CMC-544)

Study Locations (20)

Texas

  • UT Southwestern University Hospital - St. Paul - Dallas
  • Zale Lipshy University Hospital - Dallas
  • UT Southwestern Medical Center - Dallas
  • The University of Texas, M. D. Anderson Cancer Center - Houston
  • University of Texas, MD Anderson Cancer Center - Houston
  • Methodist Healthcare System of - San Antonio

New Jersey

  • John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC) - Hackensack
  • John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC) - Hackensack
  • Hackensack University Medical CenteR - Hackensack
  • John Theurer Cancer Center (JTCC) at Hackensack University Medical Center (HUMC) - Hackensack
  • John Theurer Cancer Center, Hackensack University Medical Center - Hackensack

Missouri

  • Siteman Cancer Center - City of Saint Peters
  • Barnes-Jewish Hospital - St Louis
  • Washington University School of Medicine - St Louis

Illinois

  • Loyola University Medical Center, Foster G. McGraw Hospital and Satellites - Maywood

Massachusetts

  • Tufts Medical Center - Boston

Michigan

  • University of Michigan Comprehensive Cancer Center - Ann Arbor

New York

  • Memorial Sloan - Kettering Cancer Center - New York

Pennsylvania

  • Penn State Milton S Hershey Medical Center - Hershey

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2009-06-08
Est. Completion 2012-10-31
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00867087

The ClinicalTrials.gov registry entry for NCT00867087 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 199-participant average among 31 other Lymphoma, B-Cell trials with a reported enrollment target (68% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lymphoma, B-Cell appearing as the primary indexed condition, and to 2 interventions - of which rituximab is the first listed.

NCT00867087 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Texas, New Jersey, Missouri.

Frequently Asked Questions

What is clinical trial NCT00867087 about?

NCT00867087 is a clinical study titled "Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma". The purpose of this study is to evaluate inotuzumab ozogamicin in combination with rituximab prior to an autologous stem cell transplant (aSCT) in patients with relapsed/refractory diffuse large B-cell Non-Hodgkin's lymphoma.

What is the current status of trial NCT00867087?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2009-06-08. Estimated completion is 2012-10-31.

What conditions does trial NCT00867087 study?

This clinical trial studies the following conditions: Lymphoma, B-Cell.

What interventions are being tested in trial NCT00867087?

The interventions under investigation include: rituximab (DRUG), inotuzumab ozogamicin (CMC-544) (DRUG).

Who is sponsoring clinical trial NCT00867087?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00867087 being conducted?

This trial has 20 study locations across Illinois, Massachusetts, Michigan, Missouri, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lymphoma, B-Cell

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lymphoma, B-Cell

All registered trials for this condition

Illinois

All trials with a study site in Illinois

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.